Cancer-Focused Coeptis Therapeutics Turns To SPAC Deal To Uplist To NASDAQ
Cancer-Focused Coeptis Therapeutics Turns To SPAC Deal To Uplist To NASDAQ
专注于癌症的 Coeptis Therapeutics 转向 SPAC 交易向纳斯达克上市
- Coeptis Therapeutics Inc (OTC:COEP) has agreed to a $175 million merger deal with Bull Horn Holdings Corporation (NASDAQ:BHSE), a special purpose acquisition company.
- Upon completing the deal, Bull Horn will be rebranded and operate as Coeptis Therapeutics Holdings Inc. and is expected to be listed on Nasdaq under the ticker symbol COEP.
- With this transaction, expected to be completed in the third quarter, the shareholders of Coeptis will receive equity in Bull Horn valued at $175 million.
- Related: Coeptis Therapeutics Intends To Acquire Statera's TLR5 Agonist Platform.
- The merger is anticipated to push Coeptis' efforts to boost its cell therapy platforms to treat cancer.
- Coeptis is a developer of cell therapy platforms for cancer. Its product portfolio is highlighted by a cell therapy technology (CD38-GEAR-NK) and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which Coeptis is co-developing with VyGen-Bio Inc.
- CD38-GEAR-NK is a natural killer (NK) cell-based investigational therapeutic that enables combination therapy with anti-CD38 monoclonal antibodies (mAbs).
- Coeptis' current President and CEO, David Mehalick, will lead the combined company as President & CEO. The current Chief Financial Officer of Bull Horn, Chris Calise, will join the post-closing Board of Directors.
- Price Action: COEP shares are down 26.6% at $4.11 during the market session on the last check Wednesday.
- Coeptis Therapeutic(场外交易代码:COEP)已同意与之达成1.75亿美元的合并协议牛角控股公司纳斯达克股票代码:BHSE),一家特殊目的收购公司。
- 交易完成后,Bull Horn将更名为Coeptis Therapeutics Holdings Inc.,预计将在纳斯达克上市,股票代码为COEP。
- 这笔交易预计将在第三季度完成,Coeptis的股东将获得价值1.75亿美元的Bull Horn股权。
- 相关: Coeptis Therapeutics 打算收购 Statera 的 TLR5 激动剂平台。
- 预计此次合并将推动Coeptis努力加强其治疗癌症的细胞疗法平台。
- Coeptis 是癌症细胞疗法平台的开发商。其产品组合以细胞疗法技术(CD38-GEAR-NK)和针对CD38相关癌症的体外诊断(CD38-诊断)为亮点,Coeptis正在与该技术共同开发Vygen-Bio Inc。
- CD38-GEAR-NK 是一种基于自然杀手 (NK) 细胞的研究性疗法,可与抗 CD38 单克隆抗体 (mAB) 联合治疗。
- Coeptis现任总裁兼首席执行官戴维·梅哈里克将以总裁兼首席执行官的身份领导合并后的公司。Bull Horn现任首席财务官克里斯·卡利斯将在收盘后加入董事会。
- 价格走势:在周三最后一次支票的市场交易中,COEP股价下跌26.6%,至4.11美元。